Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 1998

View Archived Issues

Dimethaid Research: nine-month highlights

Roche describes new agents for neurodegenerative disorders

ABT-431, an improved therapeutic option for PD

MOR-14 exhibits protective potential against ischemic damage

Company Profile: MTR Technologies

AmBisome and DaunoXome receive additional approvals

Fujisawa outlicenses veterinary anthelmintic agent to Bayer

Astra obtains rights from Takeda to develop TxA2 antagonist

Another series of substance P antagonists discovered at Pfizer

Oral and parenteral formulations of levofloxacin now available in U.K.

KW-2170: in vitro and in vivo antitumor activity of a new pyrazoloacridone

Allelix: Q2 FY 1998 highlights

Fraxiparine now listed on Canadian health plan formularies

Cheung seeks FDA approval to begin testing of BPH treatment system

Gastric prokinetic effects and safety of EM-574 in healthy subjects

New PDE IV inhibitors for asthma reported by Celltech

Patient dosing begins in trial of Allelix's selective serotonin agonist

Meridian signs supply agreement with HGSI for cancer therapies

Cancer drug discovery alliance formed

CETP inhibitors for lipoprotein disorders discovered at Bayer

Gilead prepares orally active prodrugs of PMPA

Pipeline update from Yuhan

Nasally delivered influenza vaccine enters phase I

Low-dose oral interferon alfa: a patient-friendly treatment for chronic diseases on the horizon

hu1124 shows clinical activity in phase I for psoriasis

Fullerenol-1: a fullerene derivative for the treatment of atherosclerosis

Naturally occurring inhibitors of ICAM-1-mediated cell adhesion discovered by Taisho

Dopaminergic compound CI-1007 evaluated in schizophrenic patients

Intrathecal SNX-111 for acute postoperative pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 10, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026